Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA final pediatric research list retains same 23 OTCs as March draft.

This article was originally published in The Tan Sheet

Executive Summary

MONOGRAPHed OTCs ON FDA PEDIATRIC LIST NOT ELIGIBLE FOR EXCLUSIVITY, NDMA says, and asks FDA to clarify this in its final list of adult drugs for which additional data could provide health benefits for children. In recent comments on FDA's March draft list, the Nonprescription Drug Manufacturers Association notes that OTC monograph ingredients are not eligible for the six months of regulatory or patent exclusivity offered by FDA for additional research, and suggests the agency, "for clarity...should preface the final list with an explanation that the list only applies to preapproval drugs and those subject to approved applications but not to those regulated under OTC monographs."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088468

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel